These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Regulators of angiogenesis as targets for anti-angiogenic tumor therapy. Breier G; Heidenreich R; Gaumann A; Groot M; Licht A; Nicolaus A; Schmitz J; Reichmann E; Plate KH; Vajkoczy P Ann Hematol; 2002; 81 Suppl 2():S71-2. PubMed ID: 12611084 [No Abstract] [Full Text] [Related]
4. Vascular endothelial growth factor (VEGF) and its effect on angiogenesis. Jośko J; Gwóźdź B; Jedrzejowska-Szypułka H; Hendryk S Med Sci Monit; 2000; 6(5):1047-52. PubMed ID: 11208453 [TBL] [Abstract][Full Text] [Related]
5. [Mechanisms and role of lymphangiogenesis in cancer metastasis]. Dupuy E; Tobelem G Bull Cancer; 2003 Jul; 90(7):595-9. PubMed ID: 12957800 [TBL] [Abstract][Full Text] [Related]
6. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971 [TBL] [Abstract][Full Text] [Related]
7. Use of tumor-activated hepatic stellate cell as a target for the preclinical testing of anti-angiogenic drugs against hepatic tumor development. Olaso E; Vidal-Vanaclocha F Methods Mol Med; 2003; 85():79-86. PubMed ID: 12710199 [No Abstract] [Full Text] [Related]
8. Lymphatic vessels and lymphangiogenesis in female cancer: mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review). Schoppmann SF; Horvat R; Birner P Oncol Rep; 2002; 9(3):455-60. PubMed ID: 11956609 [TBL] [Abstract][Full Text] [Related]
9. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Partanen TA; Paavonen K Microsc Res Tech; 2001 Oct; 55(2):108-21. PubMed ID: 11596156 [TBL] [Abstract][Full Text] [Related]
10. Advances in the use of angiogenesis inhibitors in cancer. Pinedo HM Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080 [No Abstract] [Full Text] [Related]
11. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Loges S; Mazzone M; Hohensinner P; Carmeliet P Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675 [TBL] [Abstract][Full Text] [Related]
12. Molecular control of lymphatic metastasis. Achen MG; Stacker SA Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975 [TBL] [Abstract][Full Text] [Related]
16. The clinical implications of angiogenesis in the treatment of cancer. Aoun E; Taher A J Med Liban; 2002; 50(1-2):32-8. PubMed ID: 12841311 [TBL] [Abstract][Full Text] [Related]
18. [Angiogenesis, lymphangiogenesis, and tumor progression]. Hawighorst T Zentralbl Gynakol; 2002 Nov; 124(11):497-505. PubMed ID: 12796842 [TBL] [Abstract][Full Text] [Related]
19. Endothelial survival factors as targets for antineoplastic therapy. Reinmuth N; Stoeltzing O; Liu W; Ahmad SA; Jung YD; Fan F; Parikh A; Ellis LM Cancer J; 2001; 7 Suppl 3():S109-19. PubMed ID: 11779081 [TBL] [Abstract][Full Text] [Related]
20. [Expression of vascular endothelial growth factor and its receptor (Flt-1) in breast carcinoma]. Wu H; Li Y; Zhu G; Zhang L; Zhang X; He X Zhonghua Yi Xue Za Zhi; 2002 May; 82(10):708-11. PubMed ID: 12133473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]